Academic Journal
View in EDS

Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice

Bibliographic Details
Title: Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice
Authors: Orietta Zaniolo, Germano Bettoncelli, Giancarlo Bosio, Lorenzo Mantovani, Riccardo Pistelli, Adriano Vaghi, Marco Villa, Sergio Iannazzo, Francesco Bamfi, Vincenzo Frizzo, Roberto Walter Dal Negro
Source: Farmeconomia: Health Economics and Therapeutic Pathways, Vol 12, Iss 1, Pp 5-19 (2011)
Publisher Information: SEEd Medical Publishers, 2011.
Publication Year: 2011
Collection: LCC:Medicine (General)
Subject Terms: copd, budget impact analysis, gold guidelines, italian real clinical practice, Medicine (General), R5-920
More Details: Background: Chronic Obstructive Pulmonary Disease (COPD) affects about 4.5% of the Italian population, representing one of most burdensome public health problems. Literature data report an annual health care expenditure ranging between € 1,300 and € 4,500 per patient, of which drug costs are a limited share. In 1998 the WHO started GOLD program in order to ameliorate COPD patient management. As a part of his program, periodically updated guidelines are produced with the aim of defining an efficient diagnostic-therapeutic pathway managed by a multidisciplinary team and based on the optimization of the use of drugs and diagnostic tests and the reduction of exposure to risk factors. Objective: to estimate the economic consequences of GOLD guidelines adoption in the Italian clinical practice. Methods: a decision analytic model capable of calculating the impact on the National Health Service budget of an ameliorated adherence to GOLD guidelines (GOLD GL strategy), basing on the needed variations in health care strategies on a defined patient cohort treated with the current approach (CURRENT strategy). The simulation runs on a cohort representing Italian COPD patients over 45 years who transit through 5 Markov health states (4 GOLD stages and death), according to patient characteristics (age, gender, FEV1), with a time horizon of 3 years. Stage-specific drug consumption of the CURRENT strategy is based on data of 3,113 patients collected by three Health Local Units involved in a larger clinical audit project. The consumption of other health resources, i.e. medical visits and inpatient care, is estimated based on a multicentre observational Italian study. The GOLD GL strategy includes spirometry-based staging on the totality of the simulated patients, the development of a therapeutic strategy including the redefinition of pharmacological therapy based on guideline recommendations and experts opinion, and variation of other health resources consumption based on observational data. Costs of health care resources are calculated based on published micro-costing analysis and current prices and tariffs. Results: the model estimates an adjunctive cost of about 19 million of Euros with the GOLD GL strategy, just for the the spirometry-based restaging of about 40% of the over 1 million and 250 thousand prevalent Italian COPD patients. Furthermore, in the first year of the analysis, the redefinition of the best clinical management strategy for all patients would cost about 100 million Euros, which are to be added to the more than 320 million Euros associated with adaptation of the GOLD stage specific pharmacological therapy, consisting mainly in a higher usage of long-acting beta agonist/corticosteroid combinations, only partially offset by the lower prescription of corticosteroid alone. Based on Italian observational data, the consumption of other health care resources with the GOLD GL strategy is reduced by about 44%, reflected in an estimated cost saving of more than 850 millions of Euros. For the first analysis year, the net cost saving associated with full GOLD guideline adoption is estimated equal to 410 millions of Euros; this value decreases by 11% and 21% respectively in the second and third years. Conclusion: our model estimates that the adoption of GOLD guidelines in the Italian clinical practice is associated to an average cost saving of about 300 Euros per patient/year.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2240-256X
Relation: https://journals.seedmedicalpublishers.com/index.php/FE/article/view/94; https://doaj.org/toc/2240-256X
DOI: 10.7175/fe.v12i1.94
Access URL: https://doaj.org/article/e2c25b18f40f4b108824b4fb9a977037
Accession Number: edsdoj.2c25b18f40f4b108824b4fb9a977037
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=2240256X&ISBN=&volume=12&issue=1&date=20111101&spage=5&pages=5-19&title=Farmeconomia: Health Economics and Therapeutic Pathways&atitle=Estimation%20of%20economic%20consequences%20of%20GOLD%20guidelines%20adoption%20in%20the%20Italian%20clinical%20practice&aulast=Orietta%20Zaniolo&id=DOI:10.7175/fe.v12i1.94
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/e2c25b18f40f4b108824b4fb9a977037
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.2c25b18f40f4b108824b4fb9a977037
RelevancyScore: 868
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 867.787231445313
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Orietta+Zaniolo%22">Orietta Zaniolo</searchLink><br /><searchLink fieldCode="AR" term="%22Germano+Bettoncelli%22">Germano Bettoncelli</searchLink><br /><searchLink fieldCode="AR" term="%22Giancarlo+Bosio%22">Giancarlo Bosio</searchLink><br /><searchLink fieldCode="AR" term="%22Lorenzo+Mantovani%22">Lorenzo Mantovani</searchLink><br /><searchLink fieldCode="AR" term="%22Riccardo+Pistelli%22">Riccardo Pistelli</searchLink><br /><searchLink fieldCode="AR" term="%22Adriano+Vaghi%22">Adriano Vaghi</searchLink><br /><searchLink fieldCode="AR" term="%22Marco+Villa%22">Marco Villa</searchLink><br /><searchLink fieldCode="AR" term="%22Sergio+Iannazzo%22">Sergio Iannazzo</searchLink><br /><searchLink fieldCode="AR" term="%22Francesco+Bamfi%22">Francesco Bamfi</searchLink><br /><searchLink fieldCode="AR" term="%22Vincenzo+Frizzo%22">Vincenzo Frizzo</searchLink><br /><searchLink fieldCode="AR" term="%22Roberto+Walter+Dal+Negro%22">Roberto Walter Dal Negro</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Farmeconomia: Health Economics and Therapeutic Pathways, Vol 12, Iss 1, Pp 5-19 (2011)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: SEEd Medical Publishers, 2011.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2011
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Medicine (General)
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22copd%22">copd</searchLink><br /><searchLink fieldCode="DE" term="%22budget+impact+analysis%22">budget impact analysis</searchLink><br /><searchLink fieldCode="DE" term="%22gold+guidelines%22">gold guidelines</searchLink><br /><searchLink fieldCode="DE" term="%22italian+real+clinical+practice%22">italian real clinical practice</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine+%28General%29%22">Medicine (General)</searchLink><br /><searchLink fieldCode="DE" term="%22R5-920%22">R5-920</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background: Chronic Obstructive Pulmonary Disease (COPD) affects about 4.5% of the Italian population, representing one of most burdensome public health problems. Literature data report an annual health care expenditure ranging between € 1,300 and € 4,500 per patient, of which drug costs are a limited share. In 1998 the WHO started GOLD program in order to ameliorate COPD patient management. As a part of his program, periodically updated guidelines are produced with the aim of defining an efficient diagnostic-therapeutic pathway managed by a multidisciplinary team and based on the optimization of the use of drugs and diagnostic tests and the reduction of exposure to risk factors. Objective: to estimate the economic consequences of GOLD guidelines adoption in the Italian clinical practice. Methods: a decision analytic model capable of calculating the impact on the National Health Service budget of an ameliorated adherence to GOLD guidelines (GOLD GL strategy), basing on the needed variations in health care strategies on a defined patient cohort treated with the current approach (CURRENT strategy). The simulation runs on a cohort representing Italian COPD patients over 45 years who transit through 5 Markov health states (4 GOLD stages and death), according to patient characteristics (age, gender, FEV1), with a time horizon of 3 years. Stage-specific drug consumption of the CURRENT strategy is based on data of 3,113 patients collected by three Health Local Units involved in a larger clinical audit project. The consumption of other health resources, i.e. medical visits and inpatient care, is estimated based on a multicentre observational Italian study. The GOLD GL strategy includes spirometry-based staging on the totality of the simulated patients, the development of a therapeutic strategy including the redefinition of pharmacological therapy based on guideline recommendations and experts opinion, and variation of other health resources consumption based on observational data. Costs of health care resources are calculated based on published micro-costing analysis and current prices and tariffs. Results: the model estimates an adjunctive cost of about 19 million of Euros with the GOLD GL strategy, just for the the spirometry-based restaging of about 40% of the over 1 million and 250 thousand prevalent Italian COPD patients. Furthermore, in the first year of the analysis, the redefinition of the best clinical management strategy for all patients would cost about 100 million Euros, which are to be added to the more than 320 million Euros associated with adaptation of the GOLD stage specific pharmacological therapy, consisting mainly in a higher usage of long-acting beta agonist/corticosteroid combinations, only partially offset by the lower prescription of corticosteroid alone. Based on Italian observational data, the consumption of other health care resources with the GOLD GL strategy is reduced by about 44%, reflected in an estimated cost saving of more than 850 millions of Euros. For the first analysis year, the net cost saving associated with full GOLD guideline adoption is estimated equal to 410 millions of Euros; this value decreases by 11% and 21% respectively in the second and third years. Conclusion: our model estimates that the adoption of GOLD guidelines in the Italian clinical practice is associated to an average cost saving of about 300 Euros per patient/year.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2240-256X
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://journals.seedmedicalpublishers.com/index.php/FE/article/view/94; https://doaj.org/toc/2240-256X
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.7175/fe.v12i1.94
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/e2c25b18f40f4b108824b4fb9a977037" linkWindow="_blank">https://doaj.org/article/e2c25b18f40f4b108824b4fb9a977037</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.2c25b18f40f4b108824b4fb9a977037
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.2c25b18f40f4b108824b4fb9a977037
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.7175/fe.v12i1.94
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 15
        StartPage: 5
    Subjects:
      – SubjectFull: copd
        Type: general
      – SubjectFull: budget impact analysis
        Type: general
      – SubjectFull: gold guidelines
        Type: general
      – SubjectFull: italian real clinical practice
        Type: general
      – SubjectFull: Medicine (General)
        Type: general
      – SubjectFull: R5-920
        Type: general
    Titles:
      – TitleFull: Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Orietta Zaniolo
      – PersonEntity:
          Name:
            NameFull: Germano Bettoncelli
      – PersonEntity:
          Name:
            NameFull: Giancarlo Bosio
      – PersonEntity:
          Name:
            NameFull: Lorenzo Mantovani
      – PersonEntity:
          Name:
            NameFull: Riccardo Pistelli
      – PersonEntity:
          Name:
            NameFull: Adriano Vaghi
      – PersonEntity:
          Name:
            NameFull: Marco Villa
      – PersonEntity:
          Name:
            NameFull: Sergio Iannazzo
      – PersonEntity:
          Name:
            NameFull: Francesco Bamfi
      – PersonEntity:
          Name:
            NameFull: Vincenzo Frizzo
      – PersonEntity:
          Name:
            NameFull: Roberto Walter Dal Negro
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Type: published
              Y: 2011
          Identifiers:
            – Type: issn-print
              Value: 2240256X
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Farmeconomia: Health Economics and Therapeutic Pathways
              Type: main
ResultId 1